Keerti Bio Medica Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 10-07-2024
- Paid Up Capital ₹ 0.10 M
as on 10-07-2024
- Company Age 19 Year, 29 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 Cr
as on 10-07-2024
- Revenue -40.55%
(FY 2017)
- Profit -470.89%
(FY 2017)
- Ebitda -122.41%
(FY 2017)
- Net Worth -48.94%
(FY 2017)
- Total Assets -27.58%
(FY 2017)
About Keerti Bio Medica
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 Cr.
Yerramreddy Rao and Usharani Yerramreddy serve as directors at the Company.
- CIN/LLPIN
U73100AP2005PTC048114
- Company No.
048114
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Nov 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Krishna, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Keerti Bio Medica?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yerramreddy Rao  | Director | 21-Nov-2005 | Current |
| Usharani Yerramreddy | Director | 21-Nov-2005 | Current |
Financial Performance and Corporate Structure Insights of Keerti Bio Medica.
Keerti Bio Medica Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 40.55% decrease. The company also saw a substantial fall in profitability, with a 470.89% decrease in profit. The company's net worth observed a substantial decline by a decrease of 48.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Keerti Bio Medica?
In 2017, Keerti Bio Medica had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Usha Medi-Soft Private LimitedActive 24 years 1 month
Yerramreddy Rao and Usharani Yerramreddy are mutual person
- Usha Cardiac Centre LimitedActive 30 years 26 days
Yerramreddy Rao and Usharani Yerramreddy are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 01 Apr 2018 | ₹1.00 Cr | Open |
Ikf Finance Limited Creation Date: 10 Dec 2013 | ₹1.00 Cr | Open |
How Many Employees Work at Keerti Bio Medica?
Unlock and access historical data on people associated with Keerti Bio Medica, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Keerti Bio Medica, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Keerti Bio Medica's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
